



Paul Ernest N. de Leon, MDM Chief, Research & Development Management Division

Technology Facilitation Consultative Meeting to address the Challenges of COVID-19 Pandemic

ARCHER Program

ADDRESSING AND RESPONDING TO COVID-19 THROUGH HEALTH RESEARCH PROGRAM



Vaccine-Related Initiatives



Repurposing of Existing Drugs, Supplements and other Formulations and Clinical Trials of Candidate Drugs/Formulations



Facility, Laboratory, and Hospital Equipment Enhancement

COVID Behaviour Studies



Diagnostics and Kit Validation Studies



AI/ICT-Driven Models and Prediction Studies




Regulatory Studies



Other COVID-Related (Public) Health Researches

59

health research projects related to COVID-19 supported under the ARCHER program as of July 30, 2021





Enhancing and expanding the country's COVID-19 testing capacity

Research to provide an affordable and accessible program of COVID-19 testing for the Filipino people.



Providing support to COVID-19 healthcare workers

Innovations that aim to minimize the risk of infection among healthcare workers and ensure their safety



Mapping the spread of COVID-19

Leveraging ICT for health and OMIC technologies to survey or forecast the spread of the disease for evidence informed strategies



Research on possible COVID-19 treatments

Conducting laboratory and clinical trials; and participating in global initiatives to find possible treatment regimens against COVID-19




Participation in the World Health Organization Treatment Trial An Intercontinental Collaborative Trial for Repurposed Antivirals



A total of 1315 subjects have joined the megatrial in the Philippines, with 730 patients enrolled in public hospitals and 585 in private hospitals as of January 31, 2021



Interim results of the first study shows no significant effect by hydroxychloroquine, lopinavir/ritonavir and interferon among COVID-19 patients confined in hospitals, while the analysis on the study on Remdesivir is still ongoing.



Second phase of the study already started, which will evaluate the following antivirals: Artemether, Imatinib, and Infliximab.



Research and collaborations for COVID-19 vaccines

Participation in ongoing global initiatives for vaccine clinical trials, collaborations and local studies to determine effectiveness of vaccination, development of a roadmap to advance the country's vaccine self-sufficiency



Ongoing final preparations for the local launch of the WHO SVT this month

02 Signed a MOA on LGU support for the clinical trials with the DILG

Conducted coordination meetings with NCR
Mayors to identify secondary sites, possible
referral hospitals for patients who will
experience ADRs and other specific support

WHO Solidarity Vaccine Trial

04

Conducted online trainings for health workers and staff on COVID-19 Good Clinical Practice (GCP) and COVID-19 vaccination prepared by the hospital site team leaders and WHO



'Mix-and-match'

A study evaluating the safety and immunogenicity of mixing different COVID-19 vaccines and vaccine platforms in Filipino adults

- Ongoing SJREB and IRB review. 01 Revisions are being made on the protocol in line with the comments raised by the boards.

Ongoing coordination with DOH 02 regarding study site requests, project endorsement to the LGUs and vaccine supply.

03

Ongoing coordination with labs/hospitals that will conduct the immunogenicity assays.



Philippine Vaccine Effectiveness Project:

A Post-COVID-19 Vaccination Surveillance Among Filipino Adults



Ongoing recruitment of participants, with 1,724 participants recruited at the UP-PGH site as of August 13



Started the anti SARS-CoV-2 antibody testing among unvaccinated and vaccinated participants, 1st week of August



Designated project site leaders for all 12 study sites



Establishing the Virology and Vaccine Institute of the Philippines

The VIP bill or House Bill 9559, has already passed its third and final reading on the congress.

02 Eight research and development projects under the VIP has officially commenced last July 1, 2021

03 Balik scientist experts are also being sought to partner with the VIP in order to further expand its capacities--to date, seven (7) of them have already signed their contracts.



